platoseed
โ† All companies
Enjamb Labs logo

Enjamb Labs

Active

Full stack AI Agents accelerating Biopharma R&D

Spring 2026Founded 20252 peopleSan Francisco, CA, USA
AI insightcan contain mistakes
Biopharma Clinical Trial AutomationSaaSBiopharma companies and clinical researchMedium competition
Moat
Regulatory compliance expertise and audit trail infrastructure create defensibility in highly regulated space.
Key risk
Regulatory scrutiny on AI-generated regulatory documents; pharma building internal AI could reduce TAM.
Why now
Clinical trial timelines and costs drive urgent automation of preclinical to approval workflows.
Competitors
Veeva, Medidata, In-house pharma automation

About

Enjamb puts agents across the entire drug program, from preclinical research through clinical trials and approval. Our agents synthesize up-to-date clinical evidence from the literature and real-world data to pinpoint the right endpoints and patient populations; draft and audit regulatory documents like INDs, protocols, SAPs, and NDAs; and run the statistical programming behind them, including SDTM, ADaM, TFLs, and QC, all in one auditable workspace that cuts months off the path from preclinical to clinic and clinic to market.

Founders ยท 2

Maadhav Deekshitha
Maadhav DeekshithaFounder

Maadhav Deekshitha is an ML researcher working at the intersection of AI and high-performance computing. He was the youngest person to work at the AI Innovation Lab at Dell Technologies, where he developed machine learning models on top of supercomputing infrastructure. He also became one of the youngest contributors in R&D at Broadcom, working on state-of-the-art ASIC systems.

Rayan Mubarak
Rayan MubarakFounder

Rayan is an ML and neuroscience researcher who has published first-authored papers and presented at premier conferences, including SOT and the International Society for Computational Biology. His neuroscience work spans five academic labs across UF and FIU, where he focused on developing therapeutics for pesticide poisoning. He also developed DeepImmunoGene, an ML framework for detecting lung cancer immunotherapy biomarkers that outperforms SOTA by 20%.

Launch

Launched on Y Combinator ยท May 2026
View launch post โ†—

Enjamb is an agentic platform for biopharma R&D that runs the entire drug program, from synthesizing clinical evidence and designing trials to drafting regulatory documents and statistical programming, cutting months off the path from preclinical to clinic and clinic to market.

Enjamb launches Enjamb Labs, a browser-based, agentic workspace that unifies the drug program from preclinical through regulatory approval. It synthesizes clinical evidence, drafts/audits regulatory documents, and runs statistical programming to carry context across the entire process.

Formerly โ€œEnjamb Labs Incโ€, โ€œEnjambโ€

B2BAI-powered Drug DiscoveryB2BBiotechAI

Related startups

Also in Spring 2026